Preventative CardiologyEmerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)
Section snippets
Methods
The study protocol and outcome measures for the Treating to New Targets (TNT) study have been published previously.5 In brief, patients with clinically manifest CAD commenced 8 weeks of open-label treatment with atorvastatin 10 mg/day. After this run-in period, 10,001 patients with low-density lipoprotein cholesterol levels <130 mg/dl (<3.4 mmol/L) were randomized in a double-blind design to therapy with either 10 mg or 80 mg of atorvastatin per day and followed for a median of 4.9 years.
Results
The clinical characteristics of the 3 study groups are presented in Table 1. Patients with incident DM during follow-up and those with DM at baseline had a higher mean BMI, mean systolic blood pressure, and higher prevalence of metabolic syndrome than those without DM at baseline and without incident DM during follow-up. These differences in clinical characteristics of study patients who did versus those who did not develop incident DM were comparable to what we have previously reported in the
Discussion
Our results suggest that plasma levels of several emerging biomarkers are either higher or lower in patients with incident DM compared with those without incident DM. However, after adjusting for DM risk factors, we found that only adiponectin and Lp-PLA2 remained independently associated with incident DM.
Many studies have tested the hypothesis that circulating biomarkers may predict incident DM.6 However, very few, if any, have tested this hypothesis in statin-treated patients with CAD. A
Disclosures
Dr. Arsenault holds a junior scholar award from the Fonds de recherche du Québec: Santé (FRQS). Dr. Arsenault has received consulting fees/honoraria from Pfizer. Dr. Kohli has received consulting fees/honoraria from Summer Street Research Partners, Consultant Live, Amgen, and Pfizer. Dr. Lambert has received consulting fees/honoraria from Pfizer Inc, Sanofi/Regerenon and Amgen. Dr. Waters has received consulting fees/honoraria from Pfizer Inc, Servier, Roche, Merck/Schering Plough, Biosante,
References (14)
- et al.
Diabetes: a 21st century challenge
Lancet Diabetes Endocrinol
(2014) - et al.
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials
J Am Coll Cardiol
(2011) - et al.
From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century
Metabolism
(2015) - et al.
Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease
Eur J Intern Med
(2014) - et al.
Clustering of metabolic factors and coronary heart disease
Arch Intern Med
(1999) - et al.
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers
PLoS One
(2014) - et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N Engl J Med
(2005)
Cited by (6)
Statins may increase diabetes, but benefi t still outweighs risk
2023, Cleveland Clinic Journal of MedicineAdiponectin is valuable in the diagnosis of acute heart failure with renal insufficiency
2018, Experimental and Therapeutic MedicineSignificant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis
2017, Journal of Dermatological Treatment
This study was funded by Pfizer.
See page 497 for disclosure information.